Vistagen Therapeutics Stock Today
| VTGN Stock | USD 4.24 0.30 7.61% |
PerformanceFair
| Odds Of DistressLow
|
VistaGen Therapeutics is selling at 4.24 as of the 4th of November 2025; that is 7.61 percent increase since the beginning of the trading day. The stock's open price was 3.94. VistaGen Therapeutics has only a 6 % chance of going through financial distress over the next few years and had a fair performance during the last 90 days. The performance scores are derived for the period starting the 6th of August 2025 and ending today, the 4th of November 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2016 | Category Healthcare | Classification Health Care |
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system . VistaGen Therapeutics, Inc. The company has 30.68 M outstanding shares of which 1.34 M shares are at this time shorted by private and institutional investors with about 2.09 trading days to cover. More on VistaGen Therapeutics
Moving together with VistaGen Stock
Moving against VistaGen Stock
VistaGen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Shawn JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq Industrial, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVistaGen Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand VistaGen Therapeutics' financial leverage. It provides some insight into what part of VistaGen Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
VistaGen Therapeutics (VTGN) is traded on NASDAQ Exchange in USA and employs 57 people. VistaGen Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 120.88 M. VistaGen Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.68 M outstanding shares of which 1.34 M shares are at this time shorted by private and institutional investors with about 2.09 trading days to cover.
VistaGen Therapeutics currently holds about 51.99 M in cash with (42.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Check VistaGen Therapeutics Probability Of Bankruptcy
Ownership AllocationVistaGen Therapeutics shows a total of 30.68 Million outstanding shares. Over half of VistaGen Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check VistaGen Ownership Details
VistaGen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 272.9 K | |
| Almitas Capital Llc | 2025-06-30 | 261.4 K | |
| Advisorshares Investments, Llc | 2025-06-30 | 203.1 K | |
| Boothbay Fund Management, Llc | 2025-06-30 | 177.9 K | |
| Bml Capital Management Llc | 2025-06-30 | 150 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 115.4 K | |
| State Street Corp | 2025-06-30 | 96.9 K | |
| Jane Street Group Llc | 2025-06-30 | 95.1 K | |
| Two Sigma Investments Llc | 2025-06-30 | 89.5 K | |
| Tcg Crossover Management, Llc | 2025-06-30 | 2.7 M | |
| Stempoint Capital Lp | 2025-06-30 | 2.4 M |
VistaGen Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. VistaGen Therapeutics market risk premium is the additional return an investor will receive from holding VistaGen Therapeutics long position in a well-diversified portfolio.
| Mean Deviation | 3.34 | |||
| Semi Deviation | 3.64 | |||
| Standard Deviation | 4.38 | |||
| Variance | 19.2 |
VistaGen Stock Against Markets
VistaGen Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Michelle Wellington | Vice Communications | Profile | |
| Cynthia CPA | Chief Officer | Profile | |
| Mark Ginski | Manufacturing Chemistry | Profile | |
| Erik MD | Senior Pharmacovigilance | Profile | |
| JD Esq | General Counsel | Profile | |
| Louis MD | Senior Neuroscience | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.79) | Revenue Per Share | Quarterly Revenue Growth 1.905 | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.